U.S. biotech companies Alnylam, Dicerna settle trade secrets case


Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015.



from Biotech News